4593 Stock Overview
Engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Healios K.K. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥181.00 |
| 52 Week High | JP¥264.00 |
| 52 Week Low | JP¥114.00 |
| Beta | 0.92 |
| 1 Month Change | -10.40% |
| 3 Month Change | -17.35% |
| 1 Year Change | 9.04% |
| 3 Year Change | -86.12% |
| 5 Year Change | -87.53% |
| Change since IPO | -89.28% |
Recent News & Updates
Shareholder Returns
| 4593 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 0.6% | -4.3% | 0.3% |
| 1Y | 9.0% | 23.2% | 14.6% |
Return vs Industry: 4593 underperformed the JP Biotechs industry which returned 23.2% over the past year.
Return vs Market: 4593 underperformed the JP Market which returned 14.6% over the past year.
Price Volatility
| 4593 volatility | |
|---|---|
| 4593 Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 7.2% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in JP Market | 7.4% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4593's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4593's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 64 | Hardy Kagimoto | www.healios.co.jp |
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051 for treatment of ischemic stroke and acute respiratory distress syndrome; HLCN061 for treating solid tumors; HLCR011 for the treatment of retinal pigment epithelium tear and age-related macular degeneration; and HLCL041 for liver disease. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013.
Healios K.K. Fundamentals Summary
| 4593 fundamental statistics | |
|---|---|
| Market cap | JP¥16.22b |
| Earnings (TTM) | -JP¥6.22b |
| Revenue (TTM) | JP¥549.00m |
29.7x
P/S Ratio-2.6x
P/E RatioIs 4593 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4593 income statement (TTM) | |
|---|---|
| Revenue | JP¥549.00m |
| Cost of Revenue | JP¥98.00m |
| Gross Profit | JP¥451.00m |
| Other Expenses | JP¥6.67b |
| Earnings | -JP¥6.22b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | -69.03 |
| Gross Margin | 82.15% |
| Net Profit Margin | -1,133.33% |
| Debt/Equity Ratio | 117.8% |
How did 4593 perform over the long term?
See historical performance and comparison